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A B S T R A C T   
Background and purpose: Magnetic resonance guided radiotherapy (MRgRT) has been successfully implemented 
for several routine clinical applications in adult patients. The purpose of this study is to map the potential benefit 
of MRgRT on toxicity reduction and outcome in pediatric patients treated with curative intent for primary and 
metastatic sites. 
Materials and methods: Between May and August 2020, a survey was distributed among SIOPE- and COG- 
affiliated radiotherapy departments, treating at least 25 pediatrics patients annually and being (candidate) 
users of a MRgRT system. The survey consisted of a table with 45 rows (clinical scenarios for primary (n = 28) 
and metastatic (n = 17) tumors) and 7 columns (toxicity reduction, outcome improvement, PTV margin 
reduction, target volume daily adaptation, online re-planning, intrafraction motion compensation and on-board 
functional imaging) and the option to answer by ‘yes/no’ . Afterwards, the Dutch national radiotherapy cohort 
was used to estimate the percentage of pediatric treatments that may benefit from MRgRT. 
Results: The survey was completed by 12/17 (71% response rate) institutions meeting the survey inclusion 
criteria. Responders indicated an ‘expected benefit’ from MRgRT for toxicity/outcome in 7% (for thoracic 
lymphomas and abdominal rhabdomyosarcomas)/0% and 18% (for mediastinal lymph nodes, lymph nodes 
located in the liver/splenic hilum, and liver metastases)/0% of the considered scenarios for the primary and 
metastatic tumor sites, respectively, and a ‘possible benefit’ was estimated in 64%/46% and 47%/59% of the 
scenarios. When translating the survey outcome into a clinical perspective a toxicity/outcome benefit, either 
expected or possible, was anticipated for 55%/24% of primary sites and 62%/38% of the metastatic sites. 
Conclusion: Although the benefit of MRgRT in pediatric radiation oncology is estimated to be modest, the po-
tential role for reducing toxicity and improving clinical outcomes warrants further investigation. This fits best 
within the context of prospective studies or registration trials.   
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1. Introduction 
MRgRT combines magnetic resonance imaging with a radiation 
therapy unit, allowing real-time MR-imaging, including functional im-
aging, improved soft-tissue contrast of target volumes and organs at risk 
(OARs) before, during and after treatment delivery, and online adaptive 
re-planning if necessary. Re-planning is particularly useful for sites 
affected by inter- and intrafraction motion. 
R-IDEAL phase 0 studies, defined as radiotherapy (RT) predicate 
studies [1], demonstrate that a clinical gain of MRgRT is expected by 
[2–6]: (1) a reduction of the planning target volume (PTV) expansion; 
(2) better sparing of the OARs; and/or the (3) possibility of online daily 
functional MR imaging. Early clinical results show that MRgRT has been 
successfully implemented with a re-planning and quality assurance (QA) 
workflow suitable for routine clinical application [7–10]. Typically 
reported times for MRgRT treatment delivery, when a new plan is 
generated on the daily anatomy, ranges between 40 and 50 min per 
fraction [11–13]. Two thirds of the total treatment time per fraction 
consists of patient set-up, MR imaging, MR registration with pre- 
treatment imaging, daily delineation, re-planning and plan QA. Re-
ductions in PTV margins and improvements in sparing OARs are 
potentially achievable with MRgRT compared to a cone beam computed 
tomography (CBCT) guided workflow [10,14]. 
Current applications for magnetic resonance guided radiotherapy 
(MRgRT) are focused on adults, particularly for moving targets in the 
abdomen and pelvis, while MRgRT in pediatrics is limited to two case- 
reports [15,16]. The first addresses the treatment of a 3-year old girl 
with a rhabdomyosarcoma near the diaphragm which illustrates how 
the treated volume was reduced by MRgRT [15] while the second de-
scribes the treatment of a 1.5-years old male with a rhabdoid tumor of 
Table 1 
Percentage of survey responders (N = 12) expecting a benefit for the five functionalities of MRgRT compared to CBCT-guided photon or proton therapy for different 
areas in the body and corresponding pediatric tumor scenarios. A percentage of ≤25% (=3/12) was marked as ‘no’ benefit, a percentage between 25% and 75% was 
assigned to a ‘maybe benefit’ (in italic), and ≥75% (=9/12) as ‘expected clinical benefit’ (in bold).  
Brain PTV margin 
reduction 
Daily adaptation of the 
target volume 
delineation 
Online replanning for 




during the session 
Primary RT, type diffuse midline glioma 33% 0% 0% 17% 58% 
Primary RT, type craniopharyngioma 42% 50% 42% 17% 33% 
Post-operative with tumor in situ, type posterior fossa 
ependymoma 
50% 17% 25% 17% 50% 
Post-operative with tumor in situ, type 
craniopharyngioma 
42% 42% 42% 17% 33% 
Post-operative without tumor in sity, type high-grade 
glioma 
33% 25% 25% 17% 50% 
Craniospinal RT, no macroscopic tumor in situ 8% 0% 8% 25% 17% 
Craniospinal RT, with metastatic laesions in situ 33% 25% 42% 25% 25%  
Head & Neck      
Primary RT, type parameningeal rhabdomyosarcoma 50% 33% 50% 17% 58% 
Primary RT, type nasopharynx 42% 58% 50% 17% 50% 
Post-operative RT, type parotid gland 33% 0% 25% 17% 8% 
Post-operative RT, type neuroblastoma 25% 8% 42% 25% 8%  
Thorax      
Primary RT, type mediastinal germ cell tumor 67% 67% 67% 67% 50% 
Primary RT, type lymphoma 75% 67% 67% 67% 50% 
Post-operative RT, type Ewing sarcoma arising from rib 50% 33% 33% 67% 8% 
Whole lung RT with tumor in situ, type mets from 
Ewing or Wilms 
17% 17% 33% 42% 25% 
Whole lung RT without tumor in situ, type Ewing or 
Wilms 
17% 17% 33% 42% 17%  
Abdomen      
Primary RT, type rhabdomyosarcoma 100% 75% 83% 67% 58% 
Post-operative RT with tumor in situ, type 
neuroblastoma 
83% 50% 83% 58% 50% 
Post-operative RT without tumor in situ, type Wilms 
tumor or neuroblastoma 
50% 17% 58% 42% 0% 
Whole abdomen irradiation with tumor in situ, type 
rhabdomyosarcoma or desmoplastic small blue 
round cell tumor 
17% 25% 42% 50% 42% 
Whole abdomen irradiation without tumor in situ, type 
Wilms tumor 
8% 8% 33% 33% 0%  
Pelvis      
Primary RT, type Ewing of pelvic bones 58% 67% 75% 33% 50% 
Primary RT, type rhabdomyosarcoma of prostate/ 
bladder region 
83% 75% 83% 58% 58% 
Post-operative RT, type Ewing of pelvic bones 17% 17% 42% 17% 17% 
Post-operative RT, type rhabdomyosarcoma of 
prostate/bladder region 
50% 50% 67% 58% 17%  
Extremities      
Primary or pre-operative RT, type rhabdomyosarcoma 
or Ewing sarcoma 
75% 42% 33% 25% 42% 
Post-operative with tumor in situ, type 
rhabdomyosarcoma or Ewing sarcoma 
58% 25% 33% 25% 42% 
Post-operative without tumor in situ, type 
rhabdomyosarcoma or Ewing sarcoma 
33% 8% 17% 17% 8%  
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the liver illustrating the possibility of hypofractionation by the online 
adaptive workflow [16]. 
MRgRT is a new technology on the market and as for all new tech-
niques the added value has to be assessed. Whether MRgRT can enhance 
the dosimetric therapeutic index in pediatrics by minimizing the treat-
ment volumes through improved soft-tissue visualization, daily online 
plan adaptation, real-time motion management, or daily functional MRI 
hasn’t been evaluated yet. Given the differences in treatment scenarios 
between adults and children the knowledge acquired for adults cannot 
be directly translated to the pediatric situations. In fact, unlike adults, 
the vast majority of pediatric patients with abdominal tumors like 
neuroblastoma and Wilms’ tumors receives radiotherapy in the post-
operative setting, where there is no gross tumor to target or visualize. In 
patients with residual tumors, the availability of on-board functional 
imaging (DWI, ADC) may help to individualize the treatment fractions 
[17–20]. Although rarely integrated in current pediatric protocols, a 
comprehensive local approach including adiotherapy to metastatic sites 
in children, in line with tackling oligometastatic disease in adults, is an 
interesting option for upcoming study protocols [25]. Therefore, in our 
opinion assessing the added value of MRgRT is essential to understand 
for which indications this technology should be introduced/used. 
Moreover, literature is limited to two cases with rhabdomyosarcoma 
however, for the broad spectrum of childhood tumors no data are pub-
lished. Therefore, the vision of an international group of pediatric ra-
diation oncologists on the potentially added value of MRgRT on toxicity 
reduction and outcome improvement is important. 
The purpose of this study is to estimate the potential benefit of 
MRgRT for pediatric patients treated with a curative intent on primary 
and metastatic lesions by sharing a survey among (candidate) users of 
MRgRT systems across SIOPE and COG-affiliated radiotherapy 
departments. 
2. Materials and methods 
2.1. International survey 
Between May and August 2020, a digital survey was distributed by 
email to SIOPE and COG-affiliated radiation oncologists working at 
European, US, and Canadian institutions that treat at least 25 pediatrics 
patients with radiotherapy per year and had purchased a MRgRT system. 
Departments were identified through the ViewRay website (https://vie 
wray.com/) for MRIdian and the Atlantic MR-Linac consortium member 
list for Elekta Unity users [21]. Only one responder, a radiation oncol-
ogist, per institution was asked to fill in and return the survey. 
The questionnaire, consisting of a table with 45 rows (scenarios) and 
7 columns, was designed to understand the perceived potential value of 
MRgRT for pediatric tumors treated with curative intent. Primary tu-
mors were assigned to six areas of the body: brain, head and neck, 
thorax, abdomen, pelvis and extremities. For each area common pedi-
atric radiotherapy (RT) scenarios were defined, comprising a total of 28 
scenarios across these six areas (Table 1). In addition, five metastatic 
tumor sites were defined: brain, lymph node, liver and lung metastases 
and bone (marrow) metastases with 17 common scenarios (Table 2). 
For each scenario, respondents were asked to indicate ‘yes’ or ‘no’ if 
a benefit for MRgRT was expected in reducing toxicity or improving 
clinical outcome when compared to a CBCT-guided photon or proton 
therapy workflow. In addition, participants were asked to indicate ‘yes’ 
or ‘no’ for each tumor scenario if a benefit for MRgRT was expected due 
to: 1) PTV margin reduction; 2) daily adaptation of the target volume 
delineation; 3) online re-planning for optimal OARs sparing; 4) 
compensation for intrafraction motion and 5) functional imaging during 
the session. 
Five additional questions addressed potential barriers of using 
MRgRT in pediatric patients and one question about missing clinical 
applications that had not been addressed in the survey. 
Table 2 
Percentage of survey responders (N = 12) expecting a benefit for the five functionalities of MRgRT compared to CBCT-guided photon or proton therapy for five 
metastatic tumor sites in pediatrics treated with a curative intent. A percentage of ≤25% (=3/12) was marked as ‘no benefit’, a percentage between 25% and 75% was 
assigned to ‘maybe benefit’ (in italic) and ≥75% (=9/12) as ‘expected clinical benefit’ (in bold).  
Brain PTV margin 
reduction 
Daily adaptation of the target 
volume delineation 
Online replanning for 




during the session 
Primary RT, 1–3 metastases 33% 33% 25% 17% 25% 
Primary RT, >3 metastases 17% 25% 33% 8% 17% 
Post-operative RT, (1 metastasis) 58% 42% 42% 8% 0%  
Lymph node      
Head & neck region, primary RT 67% 58% 58% 42% 50% 
Mediastinum, primary RT 92% 75% 92% 75% 67% 
Upper abdomen, para-aortic 
region, primary RT 
92% 67% 100% 75% 42% 
Upper abdomen, liver/splenic 
hilum, primary RT 
92% 83% 92% 83% 50% 
Pelvic region, iliac nodes, primary 
RT 
75% 58% 83% 58% 50% 
Inguinal region, primary RT 67% 50% 58% 42% 42%  
Lung      
Primary RT, lung mets 
(independent of whole lung RT) 
67% 67% 67% 83% 25%  
Liver      
Primary RT, liver mets 
(independent of whole liver RT) 
100% 75% 67% 92% 50%  
Bone(marrow)      
Orbit 25% 17% 33% 17% 8% 
Skull base 17% 0% 17% 8% 8% 
Skull (flat bone) 8% 0% 8% 8% 8% 
Vertebra 33% 8% 25% 8% 8% 
Pelvic bone 17% 0% 17% 8% 8% 
Extremity bones, like humerus, 
femur, tibia. 
8% 0% 8% 8% 8%  
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3. Quantification of benefit 
Allocation of expected benefits was subdivided in three categories: 
when ≤25%, 25–75%, or ≥75% of the responders answered ‘yes’, the 
expected benefit for that scenario was allocated as ‘no expected benefit’, 
’ possible expected benefit”, and ‘expected benefit’, respectively. With 
this approach, a benefit indication was obtained for each scenario. 
To put the results of the survey into a clinical perspective, an esti-
mate has been made of the percentage of pediatric patients fitting the 
categories of ‘yes’, ‘maybe’ and ‘no’ expected benefit using the Dutch 
national cohort of pediatric cancer patients treated with curative intent 
using photon therapy at UMC Utrecht and proton therapy at UMC 
Groningen between January and December 2019. Pediatric Oncology in 
the Netherlands is centralized at the Prinses Máxima Center (https 
://www.prinsesmaximacentrum.nl/en) and radiotherapy is provided 
by the two mentioned institutes. The use of the Dutch national cohort 
data for the pourpose of this study has been approved by the local ethical 
committee (approval number WAG/mb/20/500028). 
4. Results 
In total, 12 out of 17 institutions meeting the survey criteria returned 
the questionnaire (71% response rate) coming from six countries, of 
which three had already treated children while nine were candidate 
users of MRIdian or Unity at the time of questionnaire completion, 
respectively. The responders answered all questions. 
For the primary tumor sites, the responders indicated an expected 
benefit (≥75% answering ‘yes’) from MRgRT on toxicity reduction in 2/ 
28 (7%) of the scenarios considered, including thoracic lymphomas and 
rhabdomyosarcomas located in the (upper) abdomen (Fig. 1). As re-
ported in Table 1, the expected benefit from MRgRT for primary RT of 
thoracic lymphoma was explained by PTV margin reduction, daily 
adaptation of target volumes, online re-planning for optimal sparing of 
OARs, intrafraction motion management, and functional imaging during 
each fraction. For abdominal rhabdomyosarcoma the estimated benefits 
were PTV margin reduction, online re-planning for optimal sparing of 
OARs, daily adaptation of the target volumes, intrafraction motion 
management, and functional imaging during each fraction. 
A benefit of MRgRT on technical aspects such as PTV margin 
reduction, daily target volume adaptation, online replanning, intra-
fraction motion compensation was indicated for primary RT of rhab-
domyosarcoma of the prostate/bladder region, post-operative RT with 
tumor in situ like neuroblastoma, and primary or pre-operative RT like 
rhabdomyosarcoma or Ewing sarcoma in the extremities. However, re-
sponders do not expect any translation into clinical benefit for these 
indications. 
‘No’ benefit for reducing toxicity (with ≤25% of responders indi-
cating ‘yes’) was expected in 8/28 (29%) of the considered scenarios, 
mainly located in the brain. A ‘possible benefit’ was indicated by par-
ticipants in 18/28 (64%) of the scenarios. These primary tumor sce-
narios were mainly located in the head and neck, abdominal and pelvic 
region. 
None of the primary tumor scenarios scored ≥75% for expected 
clinical benefit for improved clinical outcome. However, 46% (13/28) of 
the scenarios were classified as a “possible benefit” such as patients with 
residual masses in the thorax, abdomen, or pelvis. ‘No’ benefit was ex-
pected for 54% (15/28) of the primary tumor scenarios (e.g., post-
operative irradiation of neuroblastoma, and Wilms’ tumor following 
Fig. 1. Illustration of expected benefit from MRgRT for primary pediatric tumor sites. Percentage of responders (N = 12) expecting a benefit of toxicity reduction or 
clinical outcome improvement by the use of MRgRT compared to a CBCT-guided photon or proton therapy for different areas in the body and common pediatric 
tumor scenarios. A percentage of ≤25%, 25–75% and ≥75% were considered as ‘no’, ‘possible’, and ‘expected clinical benefit’, respectively. PrimRT = primary 
radiotherapy, PostopRT = post operative radiotherapy. 
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gross total resection). 
For the metastatic tumor sites treated with curative intent, re-
sponders indicated an expected benefit (≥75% indicating ‘yes’) for 
MRgRT in reducing toxicity in 3/17 (18%) scenarios. These scenarios 
were mediastinal lymph nodes, lymph nodes located in the liver/splenic 
hilum, and liver metastases (Fig. 2). For primary RT of lymph nodes 
located in the thorax or liver/splenic hilum, a benefit from reducing 
toxicity was expected because of PTV margin reduction, daily adapta-
tion of target volumes, online re-planning for optimal sparing of OARs, 
and intrafraction motion management (Table 2). For patients with liver 
metastases, MRgRT was expected to have a benefit due to PTV margin 
reduction, intra-fraction motion management, and daily adaptation of 
target volumes. No benefit for toxicity reduction (≤25% indicating ‘yes’) 
was expected in 6/17 considered scenarios, mainly bone metastasis, 
while a ‘possible benefit’ was expected in 8/17 scenarios, including 
lymph node sites in head and neck, para-aortal, pelvic and inguinal re-
gion, and brain/lung metastases. 
None of the responders expected a clear clinical outcome benefit for 
MRgRT in all the considered metastatic scenarios. In 10/17 scenarios, a 
‘possible benefit’ was expected, generally for irradiation of lymph node 
sites. 
Concerns about the additional burden posed by the MRgRT workflow 
and the inherent features of MRgRT were indicated by a large number of 
respondents. This included the possible need for additional anesthesia 
(71%), the longer treatment times (63%), the fact that online re- 
contouring may not always be feasible due to the highly-complex 
target volumes (58%), and the risk of hearing damage in case of treat-
ment of head and neck sites due to the fact that an headset can not be 
used (42%). 
Quantification of benefit was performed by modeling the application 
of MRgRT in the 157 pediatric patients treated in the Netherlands with 
curative intent using photons (N = 113, UMC Utrecht) and protons (N =
44, UMC Groningen) in 2019. Applying the aforementioned three 
benefit categories (no, possible, yes), an expected (‘yes’) benefit for 
reducing toxicity or improving clinical outcome was assigned to 6% and 
0% of the primary sites, and 7% and 0% of the metastasic sites. A 
possible benefit for reducing toxicity or improving clinical outcome was 
estimated for 49%/24%, and 55%/38% of the primary and metastases 
sites, respectively (Fig. 3). 
5. Discussion 
The results of this international survey, focusing on the potential 
toxicity reduction and clinical outcome benefit afforded by the use of 
MRgRT for pediatric patients treated with curative intent, demonstrate a 
perceived marginal anticipated advantage when compared to CBCT- 
guided photon and proton treatments in selected scenarios. A clinical 
benefit was expected from toxicity reduction in patients with rhabdo-
myosarcoma arising in the abdomen, lymphoma or lymph nodes in the 
mediastinum, lymph nodes near the liver/splenic hilum, and liver me-
tastases in ≥75% of the survey respondents. 
Even if for thoracic lymphoma a clinical benefit of MRgRT is ex-
pected it must be noted that MRI use in lung has lagged behind because 
of inherent barriers arising from the physics of the lung itself. However, 
with new MRI sequences and the application of functional imaging, 
utility for this imaging technique in the thorax region is emerging 
[22–23]. Nevertheless, radiotherapy for (Hodgkin or non-Hodgkin) 
lymphomas is given after induction chemotherapy at a moment that 
Fig. 2. Illustration of expected benefit 
from MRgRT for metastatic tumor sites 
from pediatric tumors. Percentage of 
responders (N = 12) expecting a benefit 
of toxicity reduction or clinical outcome 
improvement by the use of MRgRT 
compared to a CBCT-guided photon or 
proton therapy for the considered met-
astatic tumor sites from pediatric can-
cers. A percentage of ≤25% (=3/12) 
was marked as ‘no benefit’, a percentage 
between 25% and 75% was assigned to a 
‘possible benefit’ and ≥75% (=9/12) as 
‘expected clinical benefit’. PrimRT =
primary radiotherapy, PostopRT = post 
operative radiotherapy, Pre-opRT = pre 
operative radiotherapy.   
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almost no or limited volume change is expected during the radiotherapy 
course. Therefore online target volume adaptation is rarely indicated in 
a setting of curative intent. 
In adults, the potential disease sites that may derive clinical benefit 
from MRgRT roughly correspond to the ones observed in this survey on 
pediatric tumors. Winkel and colleagues reported that using MRgRT PTV 
margins could be reduced and that fewer unplanned violations of high- 
dose criteria were observed with MRgRT– compared to CBCT-based 
treatments in 20 stereotactic body RT (SBRT) courses for lymph node 
metastases [10]. Tetar and colleagues demonstrated that the MRgRT 
workflow allowed PTV margin reduction in prostate cancer SBRT 
through superior soft-tissue visualization in combination with intra-
fraction motion management [12]. Also, for SBRT liver metastases, 
motion management with gating has been successfully used in MRgRT 
[24]. 
In contrast to adults, low patient numbers, complex and post- 
operative target volumes like Wilms’ tumors and rhabdomyosarcoma, 
elongated field sizes as observed in Hodgkin lymphoma and the lack of 
well-established hypofractionation regimens to treat primary or oligo-
metastatic disease, hamper the easy implementation of MRgRT in the 
field of pediatric oncology [25,26]. In addition, technical advances are 
clearly needed in order to make MRgRT more attractive for the pediatric 
patient population. For example, a larger field size and a faster volume 
delineation process, perhaps through implementing deep-learning 
methods, higher dose rates, and arc delivery techniques may reduce 
the duration of treatment sessions and improve utilization in pediatric 
patients [27–30]. Moreover, arc delivery is desired for highly conformal 
dose distributions in line with intensity modulated arc techniques 
available on CBCT machines.Also, the role of MR-guided functional 
imaging in pediatric tumors should be further explored [31–33]. How-
ever, the most important question is if this will increase at least the 
perception of a potential benefit regarding toxicity reduction and 
outcome improvement. 
There is data on offline adaptive RT planning using MR, in contrast to 
the online, daily, real-time workflow of MRgRT. Data by Merchant et al. 
have demonstrated the important role of weekly MR surveillance ex-
aminations in children with craniopharyngioma receiving RT to allow 
for re-planning in the case of cystic change during the course of treat-
ment [34]. Similarly, ad hoc offline MR may be used to inform the need 
for proton re-planning in pediatric patients with intracranial or extra-
cranial tumors [35]. However, cystic changes occurring in between MRI 
examinations can be missed for a number of fractions, hence the po-
tential benefit of daily MR imaging. In addition, several departments 
might not have easy access to MRI imaging making logistics for weekly 
imaging difficult. 
One of the possible burdens of pediatric MRgRT is the additonal need 
for anesthesia due to daily patient positioning in a narrow bore and 
longer treatment fractions when compared to a CBCT-workflow. 
Although longer sessions may also occur with proton therapy, the 
long-term effects of daily anesthesia on children have yet to be fully 
established, since concern for adverse late effects involving cognitive 
function, language, emotional reactivity, and anxiety has raised in 
recent publications [36–38]. In addition, anesthesia significantly in-
creases treatment and financial burden [39]. Another challenge is the 
patient’s inaccessibility to the anesthesiologist following placement in 
the MR Linac scanner in the case of airway problems [40]. The presence 
of a magnetic field also necessitates use of MR and radiotherapy- 
compatible anesthesia equipment, with particular attention to infusion 
pumps and inhalational anesthetic equipment [41]. 
Possible hazards from the static magnetic field exposure that could 
follow the treatment on a MRgRT platform do not differ from the ones 
that could arise from any other MR simulation (http://www.mrisafety. 
com/). Patients with reprogrammable ventriculo-peritoneal shunts 
may comprise a subset of patients that will have significant barriers to 
use MRgRT. In addition, acoustic noise is a well-known cause of 
discomfort during MRI. When hearing protection devices such as ear-
plugs/earmuffs/headphones are not properly used, the subject is at risk 
of permanent hearing damage. In principle, these devices should provide 
Fig. 3. Expected percentage of pediatric indications which may benefit of MRgRT, based on numbers from the Dutch national cohort (2019) and divided into primary 
and metastatic tumor sites. 
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sufficient protection if correctly worn [42]. However, this is not always 
the case for patients with small ear canals, neonates, and patients in 
immobilization masks undergoing MR-guided RT. In particular, MRgRT 
patients repetitively exposed to MRI are at risk of reaching critical levels 
of cumulative noise doses, especially during a long course of fraction-
ated MRgRT [43,44]. 
One potential limitation of this survey is that the results relied on the 
knowledge of twelve respondents, of which the majority are candidate 
users of MRgRT, who might have limited experience with MRgRT. 
However, we posit that the participating radiation oncologists are all 
experienced with pediatric RT, believe in MRgRT and therefore are best 
qualified to evaluate the potential role of MRgRT in pediatrics. Another 
limitation is the limited clinical experience of the responders with 
MRgRT for children so the results of the survey are not really based on 
practice. However, the conclusions are based on the best of knowledge 
available at the moment of writing on this topic. A response rate of 71% 
is comparable to response rates in other publications based on survey 
results like e.g. Huijskens [25]. Therefore, it is considered sufficient to 
roughly estimate the added value of MRgRT for pediatrics. The quanti-
fication of the percentage of patients that may benefit from MRgRT is 
based on a population-based dataset, more particularly the Dutch na-
tional cohort of children treated at the UMC Utrecht and UMC Gronin-
gen within or following SIOPE- and COG-protocols in 2019,. Therefore, 
it is expected that the number of cases per tumor scenario mentioned is 
also representative for other countries/institutes. 
Given the limited annual number of candidate cases for MRgRT, it is 
of utmost importance to share experiences among users in order to 
bridge the gap of knowledge on the application of MRgRT in pediatric 
oncology. A consortium-based collaboration will be necessary to vali-
date the clinical benefits of this new technology. 
6. Conclusions 
At present, the published scope of MRgRT in pediatric patients is 
limited to two case reports. Compared to CBCT-guided photon or proton 
treatments, expert opinions of pediatric radiation oncologists suggest 
that MRgRT may reduce toxicity in a subgroup of primary and meta-
static sites. The survey identified a sizeable pool of potential indications 
marked as ‘interesting to explore’. Therefore, we conclude that there is a 
need to perform clinical studies investigating the potential benefits of 
MRgRT in pediatric oncology. To accelerate this process, an interna-
tional consortium of investigators evaluating MRgRT in pediatrics will 
be established. 
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